Form D · Pharmaceuticals
resistanceBio, Inc.
Menlo Park, CA · CIK 0002010024
Offering snapshot reported Jan 31, 2024 · SEC filing
- Reported sold
- $12.8M Offering amount: $12.8M
- Investors reported
- 44 Form D · investor count
- Minimum accepted
- $1 Reported outside-investor minimum
- First sale
- Jan 29, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 31, 2024 | Initial | $12,776,288 | No comparison | 44 | SEC filing |
Offering details
- Securities
- Equity, Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-504031
Source: Form D, filed Jan 31, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Omri Amirav Drory | Director |
| Christopher Bulow | Director, Executive |
| Nicholas Goldner | Director, Executive |
| Kyle Lapham | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
980 O'brien Dr
Menlo Park, CA, 94025
Menlo Park, CA, 94025